Febuxostat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Febuxostat" in English language version.

refsWebsite

Global rank English rank

7web.archive.org

1^st place

4drugs.com

399^th place

333^rd place

3europa.eu

68^th place

117^th place

3fda.gov

447^th place

338^th place

2nih.gov

4^th place

2takeda.com

low place

2nice.org.uk

3,258^th place

2,666^th place

1tga.gov.au

3,984^th place

2,622^nd place

1goodrx.com

low place

1doi.org

2^nd place

1semanticscholar.org

11^th place

8^th place

1canada.ca

1,712^th place

1,063^rd place

1teijin-pharma.com

low place

1chicagotribune.com

95^th place

70^th place

1ipsen.com

low place

1usnews.com

634^th place

432^nd place

1teijin.com

low place

1genengnews.com

low place

6,625^th place

1firstwordpharma.com

low place

1researchviews.com

low place

1aafp.org

1,916^th place

1,419^th place

aafp.org (Global: 1,916^th place; English: 1,419^th place)

Love BL (2010). "Febuxostat (Uloric) for Hyperuricemia and Gout". American Family Physician. 81 (10): 1287. Retrieved 15 April 2020.

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

recalls-rappels.canada.ca

"Uloric (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes". Health Canada. 4 November 2019.

chicagotribune.com (Global: 95^th place; English: 70^th place)

Japsen B (17 August 2006). "FDA puts gout treatment on hold". The Chicago Tribune.

doi.org (Global: 2^nd place; English: 2^nd place)

Love BL, Barrons R, Veverka A, Snider KM (June 2010). "Urate-lowering therapy for gout: focus on febuxostat". Pharmacotherapy. 30 (6): 594–608. doi:10.1592/phco.30.6.594. PMID 20500048. S2CID 6617778.

drugs.com (Global: 399^th place; English: 333^rd place)

"International names for febuxostat". Drugs.com. Retrieved 25 June 2015.
"Febuxostat (Uloric) Use During Pregnancy". Drugs.com. 22 February 2019. Retrieved 17 May 2020.
"Febuxostat Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019.
"Generic Uloric Availability". Drugs.com. Retrieved 1 August 2019.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Adenuric EPAR". European Medicines Agency (EMA). 21 April 2008. Retrieved 14 September 2024.
"Adenuric: EPAR – Product Information" (PDF). European Medicines Agency. 6 August 2019.
"Adenuric: EPAR – Public Assessment Report" (PDF). European Medicines Agency. 28 May 2008.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

"Drug Safety and Availability - FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)". FDA. 21 February 2019. Retrieved 26 February 2019.
Office of the Commissioner (15 November 2017). "Safety Alerts for Human Medical Products - Febuxostat (Brand Name Uloric): Drug Safety Communication - FDA to Evaluate Increased Risk of Heart-related Death". www.FDA.gov. Archived from the original on 25 January 2018. Retrieved 17 November 2017.

accessdata.fda.gov

"Uloric label" (PDF). U.S. Food and Drug Administration. February 2009. Archived from the original (PDF) on 6 December 2011.

firstwordpharma.com (Global: low place; English: low place)

"Teijin Pharma and Astellas Pharma enter into agreement for marketing rights of TMX-67 in China and Hong Kong". First Word Pharma. 1 April 2010.

genengnews.com (Global: low place; English: 6,625^th place)

"Menarini to Market Takeda/Ipsen Gout Therapy in 41 European Countries". Genetic Engineering News. October 2009.

goodrx.com (Global: low place; English: low place)

"Febuxostat Generic Uloric". Retrieved 15 April 2020.

ipsen.com (Global: low place; English: low place)

"Adenuric (febuxostat) receives marketing authorisation in the European Union" (PDF). Archived from the original (PDF) on 26 March 2009. Retrieved 28 May 2008.

nice.org.uk (Global: 3,258^th place; English: 2,666^th place)

guidance.nice.org.uk

"Febuxostat for the management of hyperuricaemia in people with gout (TA164) Chapter 4. Consideration of the evidence". 17 December 2008. Archived from the original on 6 October 2010.

nice.org.uk

"Febuxostat for the management of hyperuricaemia in people with gout Guidance and guidelines". www.nice.org.uk. 17 December 2008. Archived from the original on 28 March 2017. Retrieved 28 March 2017.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Love BL, Barrons R, Veverka A, Snider KM (June 2010). "Urate-lowering therapy for gout: focus on febuxostat". Pharmacotherapy. 30 (6): 594–608. doi:10.1592/phco.30.6.594. PMID 20500048. S2CID 6617778.
Tomlinson B (November 2005). "Febuxostat (Teijin/Ipsen/TAP)". Current Opinion in Investigational Drugs. 6 (11): 1168–1178. PMID 16312139.

researchviews.com (Global: low place; English: low place)

"Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat". Research Views. 11 August 2011. Archived from the original on 26 June 2015.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Love BL, Barrons R, Veverka A, Snider KM (June 2010). "Urate-lowering therapy for gout: focus on febuxostat". Pharmacotherapy. 30 (6): 594–608. doi:10.1592/phco.30.6.594. PMID 20500048. S2CID 6617778.

takeda.com (Global: low place; English: low place)

Note: TAP Pharmaceuticals was a joint venture between Abbott Laboratories and Takeda that was dissolved in 2008 per this press release: "Takeda, Abbott Announce Plans to Conclude TAP Joint Venture". Takeda.
"Press release: ULORIC (TMX-67, febuxostat) Receives FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout". Teijin and Takeda. 14 February 2009.

teijin-pharma.com (Global: low place; English: low place)

"Febuxostat Storym". Teijin. Retrieved 25 June 2015.

teijin.com (Global: low place; English: low place)

"Press release: TMX-67 (febuxostat) Approved in Japan". Teijin. 21 January 2011. Archived from the original on 26 June 2015.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

usnews.com (Global: 634^th place; English: 432^nd place)

health.usnews.com

"Uloric Approved for Gout". U.S. News & World Report. Retrieved 16 February 2009.

web.archive.org (Global: 1^st place; English: 1^st place)

"Febuxostat for the management of hyperuricaemia in people with gout (TA164) Chapter 4. Consideration of the evidence". 17 December 2008. Archived from the original on 6 October 2010.
"Febuxostat for the management of hyperuricaemia in people with gout Guidance and guidelines". www.nice.org.uk. 17 December 2008. Archived from the original on 28 March 2017. Retrieved 28 March 2017.
"Uloric label" (PDF). U.S. Food and Drug Administration. February 2009. Archived from the original (PDF) on 6 December 2011.
Office of the Commissioner (15 November 2017). "Safety Alerts for Human Medical Products - Febuxostat (Brand Name Uloric): Drug Safety Communication - FDA to Evaluate Increased Risk of Heart-related Death". www.FDA.gov. Archived from the original on 25 January 2018. Retrieved 17 November 2017.
"Adenuric (febuxostat) receives marketing authorisation in the European Union" (PDF). Archived from the original (PDF) on 26 March 2009. Retrieved 28 May 2008.
"Press release: TMX-67 (febuxostat) Approved in Japan". Teijin. 21 January 2011. Archived from the original on 26 June 2015.
"Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat". Research Views. 11 August 2011. Archived from the original on 26 June 2015.

Febuxostat (English Wikipedia)

aafp.org (Global: 1,916th place; English: 1,419th place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

recalls-rappels.canada.ca

chicagotribune.com (Global: 95th place; English: 70th place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

fda.gov

accessdata.fda.gov

firstwordpharma.com (Global: low place; English: low place)

genengnews.com (Global: low place; English: 6,625th place)

goodrx.com (Global: low place; English: low place)

ipsen.com (Global: low place; English: low place)

nice.org.uk (Global: 3,258th place; English: 2,666th place)

guidance.nice.org.uk

nice.org.uk

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

researchviews.com (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

takeda.com (Global: low place; English: low place)

teijin-pharma.com (Global: low place; English: low place)

teijin.com (Global: low place; English: low place)

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

usnews.com (Global: 634th place; English: 432nd place)

health.usnews.com

web.archive.org (Global: 1st place; English: 1st place)

aafp.org (Global: 1,916^th place; English: 1,419^th place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

chicagotribune.com (Global: 95^th place; English: 70^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

genengnews.com (Global: low place; English: 6,625^th place)

nice.org.uk (Global: 3,258^th place; English: 2,666^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

usnews.com (Global: 634^th place; English: 432^nd place)

web.archive.org (Global: 1^st place; English: 1^st place)